These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6399286)

  • 21. Prevalence of secondary dapsone-resistant leprosy in Upper Volta.
    Pattyn SR; Yada A; Sansarricq H; van Loo L
    Lepr Rev; 1984 Dec; 55(4):361-7. PubMed ID: 6396476
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential antileprotic agents. 1. Inhibition of a model mycobacterial system by diaryl sulfones.
    Colwell WT; Chan G; Brown VH; DeGraw JI; Peters JH; Morrison NE
    J Med Chem; 1974 Jan; 17(1):142-4. PubMed ID: 4585972
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies.
    Rees RJ; Waters MF; Pearson JM; Helmy HS; Laing AB
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):159-69. PubMed ID: 776852
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dapsone inhibition of the bactericidal action of rifampicin on Mycobacterium leprae in mice].
    Millan J; Moulia-Pelat JP
    Med Trop (Mars); 1989; 49(4):337-41. PubMed ID: 2695734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistant leprosy--a comparison between proven dapsone and proven thiambutosine resistance.
    Waters MF; Pearson JM; Rees RJ
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):152-3. PubMed ID: 776850
    [No Abstract]   [Full Text] [Related]  

  • 26. Primary dapsone resistance in leprosy.
    Vaishnavi C; Ganguly NK; Kumar B; Kaur S; Chakravarti RN
    Indian J Lepr; 1985; 57(3):507-13. PubMed ID: 3913705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viability of Myco. leprae in the skin and bone marrow of patients with lepromatous leprosy while on dapsone or lamprene.
    Karat AB
    Lepr Rev; 1975 Jun; 46(2 Suppl):69-72. PubMed ID: 1100966
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical assessment and management of dapsone-resistant leprosy for the field worker.
    Warren G
    Lepr Rev; 1977 Jun; 48(2):113-21. PubMed ID: 330996
    [No Abstract]   [Full Text] [Related]  

  • 29. Dapsone-resistant leprosy in a population of Bamako (Mali).
    Baquillon G; Ferracci C; Saint Andre P; Pattyn SR
    Lepr Rev; 1980 Dec; 51(4):315-9. PubMed ID: 7012500
    [No Abstract]   [Full Text] [Related]  

  • 30. Ulcerating lepromatous leprosy in a patient with dapsone-resistant Mycobacterium leprae.
    McDougall AC; Rees RJ
    Lepr Rev; 1973 Jun; 44(2):59-64. PubMed ID: 4582180
    [No Abstract]   [Full Text] [Related]  

  • 31. Experimental chemotherapy in leprosy, then and now.
    Shepard CC
    Int J Lepr Other Mycobact Dis; 1973; 41(3):307-19. PubMed ID: 4136732
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence of secondary dapsone resistance in Nepal.
    Samuel NM; Samuel S; Loudon J; Neupani K; Adiga RB
    Indian J Lepr; 1984; 56(4):823-7. PubMed ID: 6398344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prevalence of dapsone-resistant leprosy in Israel.
    Levy L; Rubin GS; Sheskin J
    Lepr Rev; 1977 Jun; 48(2):107-12. PubMed ID: 330995
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined clofazimine- and dapsone-resistant leprosy. A case report.
    Kar HK; Bhatia VN; Harikrishnan S
    Int J Lepr Other Mycobact Dis; 1986 Sep; 54(3):389-91. PubMed ID: 3528345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of rifampicin and dapsone on experimental Mycobacterium leprae infections: minimum inhibitory concentrations and bactericidal action.
    Holmes IB; Hilson GR
    J Med Microbiol; 1972 May; 5(2):251-61. PubMed ID: 4555734
    [No Abstract]   [Full Text] [Related]  

  • 36. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.
    Levy L; Shepard CC; Fasal P
    Am J Trop Med Hyg; 1972 May; 21(3):315-21. PubMed ID: 4554496
    [No Abstract]   [Full Text] [Related]  

  • 37. The problem of dapsone-resistant leprosy.
    Pearson JM
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):417-20. PubMed ID: 7042605
    [No Abstract]   [Full Text] [Related]  

  • 38. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 39. DDS resistance in Ethiopia - a progress report.
    Pearson JM; Ross WF; Rees RJ
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):140-2. PubMed ID: 776848
    [No Abstract]   [Full Text] [Related]  

  • 40. Dapsone-resistant leprosy-the THELEP approach.
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):421-5. PubMed ID: 7042606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.